Drug Development
Therapeutic Pipeline
Ion channel-targeted non-opioid therapeutic pipeline. Candidates discovered through our RuCIA platform are advancing into global clinical trials.
RCI001
Target: TRPV1-Rac1 Target
TRPV1 downstream signal modulation inhibiting Rac1/NLRP3 inflammation — promotes tear secretion and corneal healing
Key Details
- •0.25% ophthalmic solution formulation
- •Faster tear secretion vs traditional steroids
- •Sjögren's syndrome model: tear secretion increase within 1 week
- •Japanese patent registered for TRPV1 active disease treatment
- •Overcomes steroid side effects (IOP elevation, redness, burning)
- •Therapeutic effects within 4 weeks
Milestones
RCI002
Target: TRPV1-MOR Biased Dual Target
MOR biased dual-target non-opioid analgesic simultaneously modulating TRPV1 and MOR — preparing CRPS Orphan Drug Designation
Key Details
- •Indications: CRPS, OA, diabetic neuropathy, CIPN, fibromyalgia
- •MOR biased agonism minimizes addiction/tolerance risk
- •Single dose: 2+ weeks pain reduction in OA model
- •No abnormal fever side effect (solved 1st-gen TRPV1 issue)
- •Efficacy at 650x lower concentration vs existing treatments
- •FDA Orphan Drug Designation (ODD) for CRPS in preparation
Milestones
RCI003
Target: Selective Modulator of Psoriasis Target Proteins
AI drug platform-based selective modulation of psoriasis target proteins — leveraging TRPV1 ion channel expertise
Key Details
- •Syntekabio AI platform (STB) for target protein analysis
- •RudaCure TRPV1 expertise applied to skin disease ion channels
- •Sogang University: compound synthesis & optimization
- •Inje University: candidate compound efficacy evaluation
- •Research period: Apr 2026 – Mar 2028
Milestones
RCI0165
Target: TRPV1 Only Target (AAV Vector)
AAV vector-based TRPV1-targeted gene therapy — single administration for long-term pain relief in animals
Key Details
- •AAV (Adeno-Associated Virus) vector-based gene therapy
- •TRPV1 ion channel single target (only target)
- •Single administration provides 3+ months sustained pain relief
- •For chronic pain management in companion animals and high-value animals (racehorses)
- •Global veterinary pain treatment market ~$2B annually